Drug Trial Radar · NCT06326047
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
299
Actual
Start
Mar 18, 2024
Primary completion
Sep 19, 2025
Study completion Oct 13, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Conditions
- Diabetes Mellitus, Type 2
Interventions
NNC0519-0130Drug
NNC0519-0130 will be administered subcutaneously.
PlaceboDrug
Placebo will be administered subcutaneously.
TrizepatideDrug
Trizepatide will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose
Locations
110 sites in 7 countries. Site status is shown where the registry gives one.
Velocity Clin Res-Chula Vista
Chula Vista, California
Valley Research
Fresno, California
310 Clinical Research
Inglewood, California
Velocity Clin Res San Diego
La Mesa, California
First Valley Med Grp Lancaster
Lancaster, California
Torrance Clin Res Inst, Inc.
Lomita, California
Pacific Clinical Studies
Los Alamitos, California
Velocity Clinical Research Westlake
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Artemis Insitute for Clin Res
San Diego, California
Med Partners, Inc.
Toluca Lake, California
UCLA Health Southbay Endocrine
Torrance, California
University Clin Investigators
Tustin, California
Diablo Clinical Research, Inc.
Walnut Creek, California
University of Colorado Hospital
Aurora, Colorado
Innovative Research of W Florida Inc.
Clearwater, Florida
Innovative Research of W FL
Clearwater, Florida
International Research Associates, LLC_Miami
Miami, Florida
Centricity Research
Columbus, Georgia
Elite Clinical Trials
Blackfoot, Idaho
Methodist Medical Center of Illinois
Peoria, Illinois
University of Iowa
Iowa City, Iowa
Centennial Medical Group
Columbia, Maryland
MD Medical Research
Oxon Hill, Maryland
Endo And Metab Cons
Rockville, Maryland
Clinvest Research
Springfield, Missouri
Mercury Str Med Grp, PLLC
Butte, Montana
Velocity Clinical Research Lincoln
Lincoln, Nebraska
Excel Clinical Network
Las Vegas, Nevada
Palm Research Center Inc-Vegas
Las Vegas, Nevada
Velocity Clinical Research Binghamton
Binghamton, New York
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Accellacare Wilmington
Wilmington, North Carolina
Diab & Endo Assoc of Stark Co
Canton, Ohio
Velocity Clin Res_Cincinnati
Cincinnati, Ohio
Velocity Clinical Research Springdale
Cincinnati, Ohio
Providence Health Partners Ctr
Dayton, Ohio
Advanced Med Res Maumee
Maumee, Ohio
Velocity Clin Res Grants Pass
Grants Pass, Oregon
Tristar Clin Investigations, PC
Philadelphia, Pennsylvania
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.